Clinical Trials
5 trialsNCT07095452 2026-05-27
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT04513639 2025-03-20
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital
Phase 2/3 Recruiting
NCT03357952 2025-02-04
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 2/3 Completed
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed